A61K 40/4217
Receptors for interleukins [il]
Official title: {Receptors for interleukins [IL]}
A61K40/4217 (Receptors for interleukins [il]) appears on 133 US grants and 347 published applications in this corpus.
Search patents in A61K- Granted patents
- 133
- Published applications
- 347
- Assignees
- 170
- Inventors
- 597
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 1 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 3 |
| 2009 | 1 | 1 |
| 2010 | 1 | 1 |
| 2011 | 0 | 3 |
| 2012 | 2 | 2 |
| 2013 | 2 | 1 |
| 2014 | 2 | 4 |
| 2015 | 2 | 2 |
| 2016 | 2 | 9 |
| 2017 | 3 | 10 |
| 2018 | 3 | 18 |
| 2019 | 7 | 27 |
| 2020 | 11 | 38 |
| 2021 | 9 | 40 |
| 2022 | 11 | 19 |
| 2023 | 20 | 44 |
| 2024 | 17 | 43 |
| 2025 | 23 | 48 |
| 2026 | 16 | 29 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Chimeric antigen receptors targeting CD127 and use thereof4 Aug 2026US 12,697,388 B2Memorial Sloan Kettering Cancer Center
- CAR-CD123 vector and uses thereof4 Aug 2026US 12,698,333 B2Ospedale Pediatrico Bambino Gesu'
- DARIC interleukin receptors21 Jul 2026US 12,686,711 B2Regeneron Pharmaceuticals, Inc.
- Chimeric Cytokine Receptors and Methods of Use8 Oct 2026US 2026/0308235 A1
- Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof1 Oct 2026US 2026/0297151 A1Medicenna Therapeutics Inc.
- Viral vectors for glioblastoma cell therapy24 Sep 2026US 2026/0284109 A1
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
- Ipsc-derived nk cell for lymphoma treatment17 Sep 2026US 2026/0273060 A1Fate Therapeutics, Inc.
Most cited
By later US patents
- Methods related to immunostimulatory nucleic acid-induced interferon110US 6,949,520 B1Coley Pharmaceutical GmbH · 2005
- Chimeric immunoreceptor useful in treating human gliomas101US 8,324,353 B2City of Hope · 2012
- Treatment of cancer using a CD123 chimeric antigen receptor95US 9,815,901 B2Novartis AG · 2017
- Treatment of cancer using a CD33 chimeric antigen receptor86US 9,777,061 B2Novartis AG · 2017
- Chimeric immunoreceptor useful in treating human cancers68US 8,497,118 B2City of Hope · 2013